Human Complement C5 Protein, His Tag (MALS verified)
分子別名(Synonym)
Complement C5,C5,CPAMD4
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human Complement C5, His Tag (CO5-H52Ha) is expressed from human 293 cells (HEK293). It contains AA Gln 19 - Cys 1676 (Accession # P01031-1).
Predicted N-terminus: Gln 19 (β chain) & Thr 678 (α chain)
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The mature form of Complement C5 is a disulfide-linked heterodimer composed of proteolytically cleaved α and β chain. Each α and β chain has a calculated MW of 73.9 kDa (β chain) and 114.4 kDa (α chain). The protein migrates as 66 kDa, 110 kDa and >180kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition, and >180 kDa under non-reducing (NR) condition (SDS-PAGE).
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
C5過敏毒素來源于補(bǔ)體C5的蛋白水解降解,是局部炎癥過程的介質(zhì)。C5前體首先通過去除4個(gè)堿性殘基進(jìn)行加工,形成由二硫鍵連接的兩條鏈,β和α。C5轉(zhuǎn)化酶通過切割α鏈激活C5,釋放C5a過敏毒素并產(chǎn)生C5b(β鏈+α'鏈)。C5轉(zhuǎn)化酶激活C5啟動(dòng)晚期補(bǔ)體成分C5-C9自發(fā)組裝成膜攻擊復(fù)合物。C5b具有C6的瞬時(shí)結(jié)合位點(diǎn)。C5b-C6絡(luò)合物是裂解絡(luò)合物組裝的基礎(chǔ)。C5a過敏毒素與C5AR1和蜱補(bǔ)體抑制劑相互作用。C5a也是一種強(qiáng)效的趨化因子,可以刺激多形核白細(xì)胞的運(yùn)動(dòng),并引導(dǎo)它們向炎癥部位遷移。
關(guān)鍵字: Complement C5;Complement C5蛋白;補(bǔ)體C5重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。